Littany Lane Investments Analyst Initiates Coverage of CollabRx with Near Term Target of $2-$3.50 Issued by Small Cap IR

New York, NY February 3rd, 2015 - SmallCapIR.com initiates coverage of CollabRx, Inc. (NASDAQ: CLRX)

CollabRX, Inc. (NASDAQ: CLRX) in our opinion has a whole lot to gain with the acquisition/merger of Medytox (OTCQB: MMMS) here’s why.

The following numbers are quoted directly from the last 10Q filings

Medytox total shareholders’ equity of $38M vs. CollabRX at $3.6M (Remember the NASDAQ letter was due to shareholders equity in CLRX dropping below 2.5M)

Medytox revenue (NET) $18.2M for the 3 months ending September 30th, 2014 vs. CollabRx $158K

Medytox (Gross) Revenue $22.8M for the 3 months ending September 30th, 2014 vs. CollabRx 176K

Recent Analyst Report issues $2-3.50 Price Target. It should be noted that this price target is given without consideration of merger. With that in mind we believe this stock could go much higher.
CLRX Analyst Report

Initial Profile:
http://smallcapir.com/?p=2508

Brief Reports on 3 other Companies Getting by with Some Help from Their Friends

Sphere 3D Corp. (NASDAQ: ANY) is a virtualization technology and data management solutions provider with a portfolio of products that address the complete data continuum from active data to data at rest. Sphere 3D enables the integration of virtual applications, virtual desktops, and storage into workflow, and allows organizations to deploy a combination of public, private or hybrid cloud strategies.

The company is expanding its client base. Read about new developments at the link that follows: http://bit.ly/--ANY-AnalystReport

22nd Century Group, Inc. (NYSE-MARKET: XXII) is a plant biotechnology company whose proprietary technology allows for the levels of nicotine and other nicotinic alkaloids (e.g., nornicotine, anatabine and anabasine) in the tobacco and plant to be decreased or increased through genetic engineering and plant breeding. The Company's technology also allows the levels of cannabinoids to be decreased or increased in the cannabis plant.

The company has begun shipment of its Smoker Friendly private label product. Get more information about this development in the report found here: http://bit.ly/--XXII-AnalystReport

FXCM, Inc. (NYSE: FXCM) is a global online provider of foreign exchange (forex) trading and related services to retail and institutional customers world-wide. At the heart of FXCM's client offering is No Dealing Desk forex trading. Clients have the advantage of mobile trading, one-click order execution and trading from real-time charts. FXCM's U.K. subsidiary, Forex Capital Markets Limited, also offers CFD products with no re-quote trading and allows clients to trade oil, gold, silver and stock indices along with forex on one platform.

The company has adopted a shareholder rights plan to achieve multiple goals. Read the details of the plan in the report that follows: http://bit.ly/--FXCM-AnalystReport

About Small Cap IR
We make the connection between sophisticated investors and high quality small cap companies. An issuer of reports written by chartered financial analysts (CFA’s) who provide a straightforward assessment of the profiled company and have pledged to remain free of influence when writing research reports. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.

For more information and services provided beyond this release please use contact information provided below.

Forward-Looking Disclaimer
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.

Compliance Procedure
Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.

A full disclaimer can be found by viewing the analyst report.

If you wish to have a company covered in more detail by our team, or wish to learn more about our services, please contact us at editor@smallcapir.com. For any urgent concerns or inquiries please contact us at editor@smallcapir.com.

Source: Small Cap IR
Contact: editor@smallcapir.com